Fortrea(FTRE)

DURHAM, NCCRO (Contract Research)

Focus: Fortrea is a large Contract Research Organization (CRO) with 10,000+ employees headquartered in Durham, NC, generating $2.8B in annual revenue. The company provides clinical trial and drug development services across a diverse pipeline of therapeutic programs.

Profile data last refreshed 6h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Employees

10001+

Open Jobs

About Fortrea

AI assessmentNot Hiring

No open roles listed right now. Follow Fortrea to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Late-stage

9 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$2.8B

Pipeline & Clinical Trials

MRD

Colorectal Cancer

N/A

Clinical Trials (1)

NCT06398743First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer

N/A

Help build intelligence for Fortrea

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Massive scale with 10,000+ employees provides stability and diverse career development across clinical, regulatory, quality, and commercial functions.
Active hiring of 196 open roles, with Clinical Operations driving 139 positions—strong demand for trial execution and operational expertise.
Public company (NASDAQ: FTRE) with $2.8B revenue base provides resources for training, benefits, and career mobility within a CRO ecosystem.

Watch Out For

Recent profitability headwind: FY 2025 net income swung to -$25.2M loss vs. +$186M profit in FY 2024, signaling margin pressure or integration challenges.
Limited pipeline visibility as CRO—career growth depends on client activity and contract wins, not proprietary drug success; minimal R&D headcount (6 roles).

Generated by Claude from Fortrea's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Adherus Dural Sealant System

Spinal Duraplasty

N/A

Clinical Trials (1)

NCT04498026Adherus™ Dural Sealant in Spinal Procedures

N/A

Renal assist device

Renal Impairment After Cardiac Surgery

N/A

Clinical Trials (1)

NCT07017933Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes

N/A

NanoDetect-TB

Tuberculosis, Pulmonary

N/A

Clinical Trials (1)

NCT05981495Clinical Evaluation of the NanoDetect-TB Mycobacterium Tuberculosis Detection Kit for the Diagnosis of Tuberculosis Disease

N/A

Cardiac mapping

Atrial Fibrillation

N/A

Clinical Trials (1)

NCT06083012Clinical and Healthcare Economic OutcoMes From ReAl-worlD Use in Europe of an AI Software During AF Ablation

N/A

Dispersion ablation + PVI

Atrial Fibrillation

N/A

Clinical Trials (1)

NCT04702451Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation

N/A

Saruparib

Locally Advanced or Metastatic Solid Tumor

Phase 1

Clinical Trials (1)

NCT06713369AZD5305 hADME in Patients With Advanced Solid Malignancies

Phase 1

AZD5492

Systemic Lupus Erythematosus

Phase 1

Clinical Trials (1)

NCT06916806A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

Phase 1

ATH-1105

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT06432647A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105

Phase 1

AZD5004

Hepatic Impairment

Phase 1

Clinical Trials (1)

NCT06813781Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004

Phase 1

D3S-001

Healthy Adult Volunteers

Phase 1

Clinical Trials (1)

NCT07093398A Phase 1 Study to Assess Food Effect on the Pharmacokinetics of D3S-001 in Healthy Adult Participants

Phase 1

GEH200520 Injection and GEH200521

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT06398730A Phase 1, Dose-Escalation, Positron Emission Tomography Study to Assess the Safety, Pharmacokinetics, Dosimetry and Biodistribution of GEH200521 (18F) Injection Co-Administered With GEH200520 Injection in Healthy Volunteers

Phase 1

AZD4512 monotherapy

B-cell Acute Lymphoblastic Leukemia (B-ALL)

Phase 1/2

Clinical Trials (1)

NCT07109219Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

Phase 1/2

ABT-301

Colorectal Cancer (Diagnosis)

Phase 1/2

Clinical Trials (1)

NCT07244705A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

Phase 1/2

VIT-2763 120 mg

Sickle Cell Disease

Phase 2

Clinical Trials (1)

NCT04817670Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease

Phase 2

Altropane

Parkinson Disease

Phase 2

Clinical Trials (1)

NCT05636852Altropane Dose for Imaging Patients With Suspected Parkinson's Disease

Phase 2

Placebo

Atherosclerotic Cardiovascular Disease

Phase 2

Clinical Trials (1)

NCT06692764A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure

Phase 2

Givinostat Hydrochloride

Duchenne Muscular Dystrophy

Phase 2

Clinical Trials (1)

NCT06769633Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old

Phase 2

GEH300079

Colorectal Cancer

Phase 2/3

Clinical Trials (1)

NCT07219238Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

Phase 2/3

AP301

Hyperphosphatemia

Phase 3

Clinical Trials (1)

NCT06933472A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

Phase 3

Tezepelumab

Chronic Rhinosinusitis With Nasal Polyps

Phase 3

Clinical Trials (1)

NCT06706817A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab

Phase 3

Leniolisib

APDS

Phase 3

Clinical Trials (1)

NCT05438407Pediatric Patients Aged 4 to 11 Years With APDS

Phase 3

Tezepelumab

Severe Asthma

Phase 3

Clinical Trials (1)

NCT06473779Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

Phase 3

Leniolisib

APDS

Phase 3

Clinical Trials (1)

NCT05693129Pediatric Patients Aged 1 to 6 Years With APDS

Phase 3

OTX-TKI

Neovascular Age-Related Macular Degeneration

Phase 3

Clinical Trials (2)

NCT07516132Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

Phase 3

NCT06223958Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

Phase 3

Sintilimab

Esophageal Squamous Cell Carcinoma

Phase 3

Clinical Trials (1)

NCT03748134Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )

Phase 3

OTX-TKI

Neovascular Age-related Macular Degeneration

Phase 3

Clinical Trials (1)

NCT06495918Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

Phase 3

Givinostat

Duchenne Muscular Dystrophy

Phase 3

Clinical Trials (1)

NCT05933057Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

Phase 3

Acalabrutinib

Chronic Lymphocytic Leukaemia

Phase 4

Clinical Trials (1)

NCT06651970Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

Phase 4

Albuterol/Budesonide

Mild Asthma

Phase 4

Clinical Trials (1)

NCT06563102Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma

Phase 4